Progression-free survival (probability)

time (months)

Axitinib (Cont) + pem/cis: 8.0 (6.5–10.0)
Axitinib (Mod) + pem/cis: 7.9 (6.2–9.5)
Pem/cis alone: 7.1 (5.8–9.2)

Axitinib (Cont) + pem/cis vs pem/cis alone
HR (95% CI) = 0.89 (0.56–1.42)
P = 0.36

Axitinib (Mod) + pem/cis vs pem/cis alone
HR (95% CI) = 1.02 (0.64–1.62)
P = 0.54

Overall survival (probability)

time (months)

mPFS, mo (95% CI)

Axitinib (Cont) + pem/cis: 8.0 (6.5–10.0)
Axitinib (Mod) + pem/cis: 7.9 (6.2–9.5)
Pem/cis alone: 7.1 (5.8–9.2)

Axitinib (Cont) + pem/cis vs pem/cis alone
HR (95% CI) = 1.05 (0.65–1.69)
P = 0.58

Axitinib (Mod) + pem/cis vs pem/cis alone
HR (95% CI) = 1.45 (0.92–2.29)
P = 0.94